In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
11 authors.
Rachel NakagawaDepartment of Cell & Tissue Biology, University of California, San Francisco, CA, USA.ORCID 0000-0001-7626-8757 Andrew BeardsleyDepartment of Cell & Tissue Biology, University of California, San Francisco, CA, USA.
Mary-Kate HaywardDepartment of Surgery and Center for Bioengineering and Tissue Regeneration, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0001-7482-5046 Vishvak SubramanyamDepartment of Biochemistry and Biophysics, University of California, San Francisco, CA, USA.ORCID 0000-0002-6144-8322 Nathaniel P MeyerDepartment of Cell & Tissue Biology, University of California, San Francisco, CA, USA.ORCID 0000-0002-8327-8563 Harrison WismerBiological Imaging Development CoLab, UCSF, San Francisco, CA, USA.
Hani GoodarziDepartment of Biochemistry and Biophysics, University of California, San Francisco, CA, USA.ORCID 0000-0002-9648-8949 Valerie M WeaverDepartment of Surgery and Center for Bioengineering and Tissue Regeneration, University of California San Francisco, San Francisco, CA, USA.ORCID 0000-0003-4786-6752 Daniel Van de MarkDepartment of Cell & Tissue Biology, University of California, San Francisco, CA, USA.
Funding
Development of CapCell Scope for Metabolic Imaging of Tissue Heterogeneity and Therapy ResponseR01EB028148 · NIBIB · DUKE UNIVERSITY · PI ANDREI GOGA, Nirmala Ramanujam · 2019 to 2026
$4.0MIn Vivo Metabolic Catastrophe Is Induced By Acute Oncogene Inhibition (PQ #22)R01CA170447 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOGA, ANDREI · 2012 to 2015
$2.4MTargeting the MYC Oncogene with CDK InhibitorsR01CA136717 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOGA, ANDREI · 2010 to 2014
$1.8MMolecular Pathology of CancerT32CA177555 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BASTIAN, BORIS C., OAKES, SCOTT A. · 2013 to 2017
$1.1MInvestigating the function of subclonal cooperation in breast cancer progressionF31CA265248 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI NAKAGAWA, RACHEL MARIE · 2021 to 2024
$114kNCI NIH HHS F31 CA265248NCI NIH HHS R01 CA136717NCI NIH HHS R01 CA170447NCI NIH HHS T32 CA177555NIBIB NIH HHS R01 EB028148
6 · The paper itselfAbstract
Non-small cell lung cancers (NSCLC) harboring common mutations in EGFR and KRAS characteristically respond transiently to targeted therapies against those mutations, but invariably, tumors recur and progress. Resistance often emerges through mutations in the therapeutic target or activation of alternative signaling pathways. Mechanisms of acute tumor cell resistance to initial EGFR (EGFRi) or KRAS
Indexed as
afatinibARS-1620BRAFV600EEGFRKRASG12CmonolayerNon-small cell lung cancer (NSCLC)osimertinibspheroidvemurafenib
Identifiers
PMID39386679
PMCPMC11463411
What OpenQuestion holds
Textmetadata
Read underepoch 390